Proprietary technology platforms
VBI Vaccines Inc's (O:VBIV) two technology platforms are designed to address hurdles in traditional vaccine design and production. The enveloped virus-like particle (eVLP) vaccine platform allows for the design of eVLP vaccines that closely mimic the target virus. The structural similarity to real viruses enables an eVLP vaccine to provide greater immunity than the traditional vaccination. The second platform is a thermostable technology used to develop vaccines and biologics that do not require a cold chain.
Moving to Phase I clinical trials in 2016
VBIV’s lead asset is a prophylactic cytomegalovirus (CMV) vaccine using its eVLP technology; VBIV is moving its CMV candidate to Phase I in H116. VBIV’s second lead asset is a therapeutic GBM vaccine candidate. At a poster presentation for the European Society of Medical Oncology (ESMO) in November, VBIV demonstrated its GBM vaccine’s ability to induce desired anti-tumor immunity in peripheral blood mononuclear cells harvested from healthy subjects and patients with GBM. VBIV plans a pre-IND meeting with the US FDA in H116.
Pending merger expands expertise and portfolio
In October, VBIV announced a reverse acquisition with SciVac Therapeutics (TO:VAC), a biopharmaceutical company with an HBV vaccine approved in Israel and several other countries. The merger brings synergistic expertise in immunology R&D and production. VBIV shares will be converted to VAC shares at a rate of 1:20.8, resulting in a combined market cap of US$140m at US$1.90 per share (US$197m on 26 October 2015), pre-financing.
To read the entire report Please click on the pdf File Below